There are many listed companies in Shanghai and Shenzhen stock markets, but as of yesterday's close, there are only 73 companies with a market value of 100 billion, most of which are financial enterprises, central enterprises and some consumer stocks with a long history. 1000 billion market value definitely needs to be super strong, or at a certain stage, such as the performance of 20 15 of stocks such as LeTV.
Huada Gene reported the highest intraday price of 258.87 yuan yesterday, with a market value of 654.38+0028 billion yuan, second only to Wen's shares on the GEM. Since 14 landed on the Growth Enterprise Market in July, the share price has risen by over 17 times compared with the issue price. At present, it is the second highest-priced stock in the two cities after Kweichow Moutai.
Among the listed companies with a market value of 100 billion, BGI's net profit should be the smallest, and its expected operating income is also less. In the first three quarters, BGI achieved operating income of 654.38+44.7 million yuan, a year-on-year increase.
15.07%, net profit was 3120,000 yuan, up 2 1.52% year-on-year. According to the annual net profit of 400 million yuan, the PE of Huada Gene is 250 times. This price-earnings ratio, if it grows very fast,
Just over 20%.
Many people are not optimistic about BGI in terms of income and profits of this scale. After BGI IPO, I was a little hesitant to enter the hundred-dollar stock camp. Opening limit on the morning of August 9th, and then withdrew. Later, it once fell below 100 yuan, when the market value was more than 40 billion.
Investors who are bearish on BGI believe that BGI has no core technology and wins by quantity. Although the company has a great reputation, it is not far from its competitors. However, another view is that BGI is the leader. If we are optimistic about biotechnology, the industry created by biotechnology in the future will be bigger than the current IT industry, then we only need to consider one problem and get stuck before the industry breaks out.
There are many ways to get stuck, such as each company investing a little, and another way is to invest in leading companies, whose success probability is obviously higher than other companies. If you watch it long enough, BGI can continue to buy even if it falls, and one day it will usher in a bumper harvest.
Of course, there is another situation, that is, a better company has been born, or a better technology has emerged than now, and a new industry giant has been born. But most investors can't guess this, and they can't give up the layout of a potential industry just because new companies may appear in the future.
Huada Gene is a phenomenal enterprise. The popularity of this company has never subsided and has been at the forefront of public opinion. Even if there is no operating income, even at the stage of making money by papers, it can always attract the attention of the public. On the one hand, it is because the gene industry this company is engaged in is high-tech in the eyes of ordinary people, and on the other hand, it is full of interest.
Huada Gene attracted a lot of PE investment before listing, and its valuation was not low at all. Since the end of 20 12, more than 50 investors have invested in BGI (including Yuan Hua College of Medicine and Yuan Hua University of Science and Technology), with a total investment of 7.2 72. 15 billion yuan. The current market value of Huada Gene proves the vision of these investors, and generally has more than four times the income.
BGI's main business income comes from four business segments: reproductive health services, basic scientific research services, complex disease services and drug research and development services. Most of the income comes from the first two, among which the basic sector.
Research service is the foundation of BGI, but in recent years, compared with competitors, the income advantage is not obvious. People are most optimistic about reproductive health services, which are growing rapidly. It is also the heaviest for Huada Gene to have such a high valuation.
The main reason. However, BGI believes that their accumulated advantages and sustained high investment in scientific research can help them complete their advantages different from their competitors.
In contrast, Berry Gene, which is most similar to BGI's business in the mainland capital market, has basically remained inactive while BGI has recently risen. It can be understood that the market gives the leader a high valuation, and it can also be understood as the market's recognition of a company with high R&D investment. However, if it is a cautious investor, it can also be understood that BGI has deviated from the fundamentals.
It must be high.